Biotech Values

[jellybean]

Thanks for the reference. Actually what they said was this The in vitro antagonistic drug- drug interactions with telaprevir, an HCV protease inhibitor telaprevir currently in phase 3 studies, are unlikely in clinical studies given the duplicity of enzymatic pathways available for delivery of the triphosphate intracellularly

So there are in vitro antagonistic drug-drug interactions. Interesting. They conclude is that these interactions won't be a problem in vivo because of the duplicity of enzymatic pathways....but they did not show that.

The other thing no one mentions is that for ever molecule of 7977 metabolized a phenol is released into the cell. Not necessarily a problem, but one never knows when a drug is dosed for months at high levels.